Objective The present study was conducted with the aim to assess and comparatively evaluate the safety and efficacy of misoprostol alone and mifepristone with misoprostol for second trimester termination of pregnancy.
Introduction
The second trimester termination of pregnancy is increasing because of increased determination of the sex linked genetic, metabolic disorders. Various surgical and medical methods have been tried for the second trimester MTP with varying success and induction abortion interval. Prostaglandins are associated with not only a high success rate but also with a short induction abortion interval. Misoprostol a newer synthetic prostaglandin E1 has proven its efficacy as an abortifacient for second trimester MTP since 1987. It is superior to all other available prostaglandins as it is stable at room temperature, requires no refrigeration, is cost effective, has fewer side effects, is a potent uterotonic and cervical ripening agent, free from bronchoconstrictive effect. It can be used by both the oral as well as vaginal route and in concurrence with other drugs as well. Mifepristone, (RU 486, a substitute 19-norethisterone derivative) by blocking the progesterone receptors causes estrogen dominance and results in intrauterine fetal death. At the same time it sensitizes the uterus to the activity of the prostaglandin. Thus, a combination of the two can significantly improve the efficacy of the misoprostol for the termination of second trimester termination of the pregnancy.
Materials and Methods
The study was conducted on selected 200 cases came for second trimester termination of pregnancy from January 2003 to October 2004. A detailed history of the case regarding menstrual, obstetric, personal, medical with special reference to cardiovascular, respiratory, GIT, endocrinal disorder and coagulopathy was obtained. General and systemic examination of the cases was done. The patients with undiagnosed adnexal masses, hypertension, diabetes, jaundice, severe anemia, heavy smokers, adrenal insufficiency, coagulopathy, on corticosteroid therapy, porphyria, sickling, hemophilia, ITP were excluded from the study.
Proper counseling a written consent were obtained following which the cases were randomly divided in two groups of 100 each. Study group received 200 lg of mifepristone on admission. After 12 h in these cases 600 lg of misoprostol was inserted vaginally and thereafter 300 lg every 3 h until the abortion occured or up to a maximum of 5 doses. Control group: the cases received misoprostol only in the same dose schedule. The cases were closely monitored for side effects if any, the onset of contraction, bleeding cervical dilatation each time before insertion of each misoprostol. Induction abortion interval, since the insertion of the first intravaginal tablet of misoprostol was noted down. The process is considered failed if abortion fails to occur in 15 h of the insertion of the first tablet of misoprostol, incomplete if part or whole of the placenta is retained. If placenta is retained for more than 2 h surgical evacuation was done. In case of failure another method medical or surgical was tried. Rh antibody was given to all the Rh negative cases at the end of the procedure. The data were analyzed.
Observations
Majority of the cases in both the groups were between 21 and 30 years of age. The mean gravidity of the cases was 3.62 ± 1.35 years in the study group and 2.9 ± 1.50 in the control group. The mean parity was 2.59 ± 1.34 and 1.79 ± 1.50 in the study and the control groups, respectively. The mean gestational age was 16.04 ± 2.57 and 19.03 ± 3.92 weeks in the study and the control groups respectively (Table 1) .
90% of the cases aborted within 9 h in the study group after the insertion of the first misoprostol tablet as against only 13% in the misoprostol alone group. All the cases in the study group aborted within 15 h in the study group as against only 79% in the control group. The mean induction abortion interval was 6.72 ± 2.26 h as compared to 12.29 ± 3.41 h in the control group. (P \ 0.001) ( Table 2) .
Success rate was 100% in both the groups. The abortion was complete in 95% of the study group while 90% in the control group. Need of other oxytocic for control of bleeding was in 14% of the control group as compared to 5% in the study group. (P \ 0.001) ( Table 3) .
How was it calculated: Mean blood loss was 61.25 ± 19.67 and 67.25 ± 20.14 ml in the study and the control group, respectively (P [ 0.05) ( Table 3) . Majority of the fetus in both the groups were aborted dead, 87 and 90%, in sac in 12% of the study group and 5% in the control group, respectively. The mean dose of the misoprostol required was significantly less in the study group 1,186 ± 291.64 lg as compared to 1,736 ± 320.20 lg in the control group, respectively (P \ 0.001) ( Table 3) . The side effects observed were mainly nausea, vomiting 10 and 14%, fever 18 and 23%, abdominal cramps 10 and 13%, flushing and diarrhea in 2% each in the study and control group, respectively (Table 4) .
Discussion
Misoprostol has proven its efficacy as an effective abortifacient for the second trimester termination of pregnancy. It is being successfully used through all the routes i.e. sublingual, oral and vaginal and in different regimens with the induction abortion interval varying from 12 h to as high as 33 h. [1] [2] [3] [4] [5] [6] [7] [8] [9] .
Combination of mifepristone with misoprostol is now widely used method for first early first trimester pregnancy termination. Priming of the uterus with mifepristone makes it more sensitive to prostaglandins. It binds with the progesterone receptors and antagonizes the actions of progesterone on prostaglandin synthesis and metabolism resulting in increase in production and decreased deactivation of prostaglandins. It also induces cervical softening thus, enhancing the efficacy of the prostaglandins as an abortifacient.
The time interval between the insertion of the first tablet of misoprostol and start of contraction was significantly shorter in the study group 4.66 ± 2.03 as against 8.18 ± 2.68 in the misoprostol alone group (P \ 0.001). The time interval between the insertion of the first tablet and the start of the bleeding was also significantly shorter in the study group 5.52 ± 2.13 h as compared to 9.98 ± 3.12 h in the control group. (P \ 0.001). The induction abortion interval was significantly shorter 6.72 ± 2.26 h in the study group while it was 12.29 ± 3.41 h in the misoprostol alone group. (P \0.001).
Rodger et al. [10] in a double blind study using 600 mg mifepristone 36 h prior to gemeprost found that the IAI was significantly reduced to 6.8 h as compared to 15.8 h in the placebo group. Similar results had been observed by other authors as well using mifepristone followed by prostaglandins [11] [12] [13] [14] [15] (Table 4) .
The success rate was 100% in the present study. The mean dose of misoprostol required was significantly less when used in combination with mifepristone as is also found in many other studies. The commonly observed side effects were nausea, vomiting, fever, abdominal cramp and diarrhea.
Conclusion
Second trimester termination of the pregnancy using combination of mifepristone and misoprostol is a safe, non invasive, highly cost effective method with a high success rate a short IAI. Pre-treatment with mifepristone adds to the effectiveness of the misoprostol as an abortifacient. The induction abortion interval is significantly shorter in the combination group 
